Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals
Biopharmaceutical
Traded as NASDAQ: ARWR
Russell 2000 Component
Headquarters Pasadena, CA
Key people

Christopher Anzalone, Ph.D., president and chief executive officer Bruce Given, M.D., chief operating officer

Ken Myszkowski, MBA, CPA, chief financial officer
Website http://arrowheadpharma.com/

Arrowhead Pharmaceuticals is a publicly traded (NASDAQ: ARWR) biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.[1][2] The company focuses on treatments for Hepatitis B, the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease.[1] The company has eight products in its pipeline, in various stages of development.[1]

ProductIndicationDevelopment phase
ARO-HBV[1]Hepatitis BIn Clinic Phase 1/2
ARO-AAT[1]Alpha-1 Antirypsin DeficiencyIn Clinic Phase 1/2
ARO-APOC3[1]HypertriglyceridemiaPre-Clinical
ARO-HIF2[1]Renal Cell CarcinomaPre-Clinical
ARO-LUNG1[1]UndisclosedPre-Clinical
ARO-ANG3[1]HypertriglyceridemiaPre-Clinical
ARO-LPA[1]Cardiovascular DiseasePre-ClinicalPartnered with Amgen
ARO-AMG1[1] Undisclosed CardiovascularPre-ClinicalPartnered with Amgen

In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis.[3][4]

In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[5]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 "arwr-10q_20170331.htm". www.sec.gov. Retrieved 2017-05-17.
  2. ↑ "8-K". www.sec.gov. Retrieved 2017-05-17.
  3. ↑ "Arrowhead buys Novartis' RNAi portfolio". Reuters. 2017-03-05. Retrieved 2017-05-17.
  4. ↑ Staff (1 April 2015). "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
  5. ↑ "Amgen, Arrowhead team up on gene-therapies for heart disease". Reuters. 2017-09-29. Retrieved 2017-05-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.